Rising compensation for biotech r&d officers

Access through your institution Buy or subscribe As the biotech industry has hit profitability in recent years, with record market values and a steady drumbeat of regulatory approvals for

its products, compensation for its executives has in turn climbed steadily. Whereas the global financial downturn produced a road bump that sidetracked many companies—and wrecked

others—recent signs show a sector that has navigated its way back onto the highway and is picking up speed. The 2013 _BioWorld Executive Compensation Report_1 tracks the annual compensation

for biopharmaceutical executives at 258 companies (including 55 non-US companies) based on filings submitted to the US Securities and Exchange Commission. Here we focus on R&D officers,

which includes such positions as chief medical officer, chief scientific officer, chief development officer, research executives, R&D executives, development executives and clinical

development executives. Table 1 ranks the top 20 earners, all from US companies, who earned anywhere from $662,000 to $2.55 million in the 2011 fiscal year. We note that the scientists

ranked number 1, 6 and 14 have in the past published original research in _Nature Biotechnology_. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access

through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink *

Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional

subscriptions * Read our FAQs * Contact customer support REFERENCES * Anonymous. _BioWorld Executive Compensation Report 2013: Trends in C-Level Salaries and Benefits in the

BioPharmaceuticals Market_ (AHC Media, Atlanta, GA, 2012). Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Michael Francisco is a Senior Editor at Nature Biotechnology.,

Michael Francisco Authors * Michael Francisco View author publications You can also search for this author inPubMed Google Scholar ETHICS DECLARATIONS COMPETING INTERESTS The author declares

no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Francisco, M. Rising compensation for biotech R&D officers. _Nat

Biotechnol_ 31, 82 (2013). https://doi.org/10.1038/nbt.2474 Download citation * Published: 09 January 2013 * Issue Date: January 2013 * DOI: https://doi.org/10.1038/nbt.2474 SHARE THIS

ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative